ReviewClinical and experimental hepatology2026
Fontan-associated liver disease in children following surgical correction of congenital heart defects.
Review in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Fontan procedure is a palliative surgical strategy used in the management of severe congenital heart defects, resulting in the creation of a single-ventricle circulation. In this physiological configuration, venous blood from the systemic circulation flows directly into the pulmonary arteries, bypassing the heart muscle. The operation is typically performed in early childhood and significantly improves long-term prognosis, enabling survival into the third decade of life and beyond. Over time, however, children and young adults develop complications related to the altered circulatory system, including chronic liver disease predominantly driven by passive hepatic congestion. This condition leads to progressive hepatic fibrosis, cirrhosis, and, in a substantial proportion of patients, hepatocellular carcinoma. Consequently, lifelong interdisciplinary specialist care, including structured hepatological follow-up, is required from early childhood. Progressive liver disease in children with altered cardiovascular physiology poses distinct diagnostic and therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.